Newcastle University Confidence in Concept 2014
Lead Research Organisation:
Newcastle University
Department Name: UNLISTED
Abstract
Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.
Technical Summary
The Confidence in Concept scheme is a key part of MRC’s translational research strategy and provides annual awards to institutions, to be used flexibly to support the earliest stages of multiple translational research projects. The award can be used by the institution to support a number of preliminary-stage translational projects. The projects supported should aim to provide sufficient preliminary data to establish the viability of an approach –– before seeking more substantive funding. It is intended to accelerate the transition from discovery research to translational development projects by supporting preliminary work or feasibility studies to establish the viability of an approach.
Organisations
People |
ORCID iD |
Publications
Alfonsa H
(2016)
Cl-out is a novel cooperative optogenetic tool for extruding chloride from neurons.
in Nature communications
Bartneck M
(2019)
The CCR2+ Macrophage Subset Promotes Pathogenic Angiogenesis for Tumor Vascularization in Fibrotic Livers.
in Cellular and molecular gastroenterology and hepatology
Brown A
(2016)
PEG-lipid micelles enable cholesterol efflux in Niemann-Pick Type C1 disease-based lysosomal storage disorder
in Scientific Reports
Brown AE
(2018)
Pharmacological activation of AMPK and glucose uptake in cultured human skeletal muscle cells from patients with ME/CFS.
in Bioscience reports
Chan SL
(2020)
Development of a Novel Inflammation-Based Index for Hepatocellular Carcinoma.
in Liver cancer
Coulthard SA
(2017)
Azathioprine with Allopurinol: Lower Deoxythioguanosine in DNA and Transcriptome Changes Indicate Mechanistic Differences to Azathioprine Alone.
in Inflammatory bowel diseases
Coulthard SA
(2016)
Liquid chromatography-mass spectrometry for measuring deoxythioguanosine in DNA from thiopurine-treated patients.
in Journal of chromatography. B, Analytical technologies in the biomedical and life sciences
De Chiara F
(2020)
Ammonia Scavenging Prevents Progression of Fibrosis in Experimental Nonalcoholic Fatty Liver Disease.
in Hepatology (Baltimore, Md.)
Dodds RM
(2018)
Mitochondrial respiratory chain function and content are preserved in the skeletal muscle of active very old men and women.
in Experimental gerontology
| Description | BH172788 - BRC Muscle and Ageing Science Study |
| Amount | £24,891 (GBP) |
| Funding ID | PDB050 |
| Organisation | National Institute for Health Research |
| Department | NIHR Biomedical Research Centre |
| Sector | Public |
| Country | United Kingdom |
| Start | 09/2017 |
| End | 03/2019 |
| Description | BH174433 - BRC Muscle Ageing Sarcopenia Study_Lifecourse (MASS): Establishing a life course cohort - diagnosis and treatment of sarcopenia |
| Amount | £227,235 (GBP) |
| Funding ID | BH174433 |
| Organisation | National Institute for Health Research |
| Department | NIHR Biomedical Research Centre |
| Sector | Public |
| Country | United Kingdom |
| Start | 06/2018 |
| End | 05/2021 |
| Description | BRC Chronic Cognitive Impairment in Cholestatic Liver Disease: Impact, Pathogenesis & Treatment |
| Amount | £262,788 (GBP) |
| Funding ID | MJ/ML/1217 - PDB064 |
| Organisation | National Institute for Health Research |
| Department | NIHR Biomedical Research Centre |
| Sector | Public |
| Country | United Kingdom |
| Start | 03/2018 |
| End | 02/2020 |
| Description | Changing network interactions in models of medically refractory epilepsy |
| Amount | £381,251 (GBP) |
| Funding ID | MR/R005427/1 |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 10/2017 |
| End | 09/2020 |
| Description | Cl-out: a novel cooperative-optogenetic strategy to control neuronal chloride |
| Amount | £594,635 (GBP) |
| Funding ID | BB/P019854/1 |
| Organisation | Biotechnology and Biological Sciences Research Council (BBSRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 10/2017 |
| End | 10/2020 |
| Description | Comparison of mitochondrial bioenergetic analysis techniques for Chronic Fatigue Syndrome / Myalgic Encephalomyelitis diagnosis |
| Amount | £21,305 (GBP) |
| Organisation | ME Association |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 05/2015 |
| End | 09/2015 |
| Description | Detection and Isolation of Circulatory Tumour Cells from Sarcome Patients |
| Amount | £65,427 (GBP) |
| Funding ID | 30015.088.043/PA/IXS |
| Organisation | The JGW Patterson Foundation |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 06/2015 |
| End | 06/2017 |
| Description | Determining the role of TLE3 in beta-cell identity and fate conversion |
| Amount | £9,792 (GBP) |
| Funding ID | 16/0005434 |
| Organisation | Diabetes UK |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 08/2016 |
| End | 08/2017 |
| Description | Developing techniques to decrease 'pro-cancer' versions of HER2 in breast cancer cells |
| Amount | £22,000 (GBP) |
| Organisation | Gateshead Health NHS Foundation Trust |
| Sector | Public |
| Country | United Kingdom |
| Start | 07/2016 |
| End | 06/2017 |
| Description | Development of pre-clinical 3D models of liver cancer to test novel therapies |
| Amount | £80,000 (GBP) |
| Organisation | W. E. Harker Foundation |
| Sector | Private |
| Country | United Kingdom |
| Start | 03/2020 |
| Description | Do the levels of deoxythioguanosine (dTG) in DNA of Autoimmune Hepatitis (AIH) patients with azathioprine correlate with clinica |
| Amount | £17,504 (GBP) |
| Organisation | Newcastle upon Tyne Hospitals NHS Charity |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 01/2017 |
| End | 05/2017 |
| Description | EIT Health: 18427 Vitality |
| Amount | £300,000 (GBP) |
| Organisation | European Commission |
| Sector | Public |
| Country | European Union (EU) |
| Start | 10/2016 |
| End | 12/2018 |
| Description | EPSRC IAA Phase 2: Exploiting the translational potential of bioinformatics driven diagnostics development |
| Amount | £82,852 (GBP) |
| Organisation | Engineering and Physical Sciences Research Council (EPSRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 04/2016 |
| End | 03/2017 |
| Description | Evaluating the HER2 status: developing assays to measure different versions of HER2 in breast cancer cells |
| Amount | £33,897 (GBP) |
| Organisation | Royal Victoria Infirmary |
| Sector | Hospitals |
| Country | United Kingdom |
| Start | 06/2016 |
| End | 03/2018 |
| Description | HARMONIzation and integrative analysis of regional, national and international Cohorts on primary Sjögren's Syndrome (pSS) towards improved stratification, treatment and health policy making |
| Amount | £10,000,000 (GBP) |
| Funding ID | 731944 - HarmonicSS - H2020-SC1-2016-2017/H2020-SC1-2016-RTD |
| Organisation | European Commission |
| Sector | Public |
| Country | European Union (EU) |
| Start | 01/2017 |
| End | 06/2020 |
| Description | HUNTER: Hepatocellular Carcinoma Expediter Network |
| Amount | £5,000,000 (GBP) |
| Funding ID | C9380/A28223 & A26813 |
| Organisation | Cancer Research UK |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 12/2018 |
| End | 11/2023 |
| Description | HUNTER: Hepatocellular Carcinoma Expediter Network |
| Amount | £736,000 (GBP) |
| Organisation | Cancer Research UK |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 12/2019 |
| Description | Investigating abnormalities in AMPK activation and mitochondrial function in primary skeletal muscle cell cultures from patients with ME/CFS |
| Amount | £85,518 (GBP) |
| Organisation | ME Research UK |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 04/2017 |
| End | 12/2019 |
| Description | Investigating the clinical implication(s) of HER2 varients in breast cancer |
| Amount | £73,620 (GBP) |
| Organisation | Susan Channon Breast Cancer Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 02/2018 |
| End | 08/2021 |
| Description | Liver Investigation: Testing Marker Unitity in Steatohepatitis (LITMUS) |
| Amount | £3,321,093 (GBP) |
| Funding ID | 777377 |
| Organisation | European Commission |
| Sector | Public |
| Country | European Union (EU) |
| Start | 10/2017 |
| End | 10/2022 |
| Description | MICA-Molecular drivers of fibrosis at the hepatic epithelial-mesenchymal barrier |
| Amount | £1,871,277 (GBP) |
| Funding ID | MR/R023026/1 |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 01/2019 |
| End | 01/2024 |
| Description | MICA: Exploring a new perspective on the mechanism of action of Glucokinase Activators in liver, a preclinical study |
| Amount | £606,933 (GBP) |
| Funding ID | MR/P002854/1 |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 01/2017 |
| End | 01/2020 |
| Description | MICA: Randomised, double-blinded, placebo-controlled, adaptive design trial of the efficacy of acipimox in patients with Mitochondrial Myopathy (AIMM) |
| Amount | £1,684,631 (GBP) |
| Funding ID | MR/R006458/1 |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 01/2018 |
| End | 10/2021 |
| Description | Mechanisms of chronic liver disease associated with hepatitis C virus genotype 3 infection |
| Amount | £80,000 (GBP) |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | |
| Description | Mitochondrial Proliferators |
| Amount | £395,088 (GBP) |
| Organisation | Morningside Venture Capital |
| Sector | Private |
| Country | China |
| Start | 06/2016 |
| Description | Mitochondrial Proliferators |
| Amount | £218,000 (GBP) |
| Organisation | Morningside Venture Capital |
| Sector | Private |
| Country | China |
| Start | 08/2019 |
| Description | Modelling inflammation and fibrosis using precision cut lung slices |
| Amount | £265,000 (GBP) |
| Organisation | GlaxoSmithKline (GSK) |
| Sector | Private |
| Country | Global |
| Start | |
| Description | Neutrophils as drivers of hepatocellular carcinoma progression - predictive biomarker and target for therapeutic intervention? |
| Amount | £140,553 (GBP) |
| Organisation | Cancer Research UK |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | |
| Description | OCA on cognitive Symptoms |
| Amount | £22,169 (GBP) |
| Organisation | Intercept Pharmaceuticals |
| Sector | Private |
| Country | United States |
| Start | 12/2014 |
| End | 11/2017 |
| Description | Obetichololic Acid for Cognitive Symptoms: The OACS Trial Programme |
| Amount | £2,500,000 (GBP) |
| Organisation | Intercept Pharmaceuticals |
| Sector | Private |
| Country | United States |
| Start | 04/2020 |
| End | 12/2024 |
| Description | PCLS Study |
| Amount | £104,598 (GBP) |
| Funding ID | 43088140 |
| Organisation | Boehringer Ingelheim |
| Sector | Private |
| Country | Germany |
| Start | 06/2018 |
| End | 05/2019 |
| Description | PCLS study |
| Amount | £94,875 (GBP) |
| Organisation | AstraZeneca |
| Department | MedImmune |
| Sector | Private |
| Country | United Kingdom |
| Start | |
| Description | PCLS study |
| Amount | £43,480 (GBP) |
| Organisation | Enleofen |
| Sector | Private |
| Country | Singapore |
| Start | |
| Description | PCLS study - Pilot |
| Amount | £16,038 (GBP) |
| Organisation | Nuformix |
| Sector | Private |
| Country | United Kingdom |
| Start | |
| Description | RESi-Sense PRF - IDRIS System: proof of concept and exploration of commercialisation routes |
| Amount | £49,967 (GBP) |
| Organisation | Engineering and Physical Sciences Research Council (EPSRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 05/2016 |
| End | 05/2017 |
| Description | Studentship (50%) Anna-Lena Ditrich |
| Amount | £28,398 (GBP) |
| Organisation | Royal Victoria Infirmary |
| Sector | Hospitals |
| Country | United Kingdom |
| Start | 03/2015 |
| End | 09/2016 |
| Description | Targeting RAS pathway medicated chemo-resistance in acute lymphoblastic leukaemia |
| Amount | £62,172 (GBP) |
| Funding ID | 30015.088.055/PA/IXS |
| Organisation | The JGW Patterson Foundation |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 02/2016 |
| End | 02/2017 |
| Description | Testing the hypothesis that LDAA reduces UV-mediated damage to mitochondrial and nuclear DNA compared to AZA |
| Amount | £44,621 (GBP) |
| Organisation | The JGW Patterson Foundation |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 06/2017 |
| End | 05/2018 |
| Description | Testing the hypothesis that LDAA reduces UV-mediated damage to mitochondrial and nuclear DNA compared to AZA |
| Amount | £44,621 (GBP) |
| Funding ID | 30015.088.0789/PA/IXS |
| Organisation | The JGW Patterson Foundation |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 06/2016 |
| End | 08/2018 |
| Description | Towards Targeting Neutrophils in Hepatocellular Carcinoma |
| Amount | £140,551 (GBP) |
| Funding ID | C18342/A24691 |
| Organisation | Cancer Research UK |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 03/2017 |
| End | 02/2021 |
| Description | Towards targeting neutrophils in hepatocellular carcinoma |
| Amount | £941,943 (GBP) |
| Funding ID | A23390 |
| Organisation | Cancer Research UK |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 03/2017 |
| End | 02/2022 |
| Description | Virtual reality intervention for children and adults with autism and anxiety |
| Amount | £44,872 (GBP) |
| Organisation | United Kingdom Research and Innovation |
| Department | Northern Accelerator |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 06/2019 |
| End | 06/2020 |
| Title | Cl-out: A novel optogenetic protein for removing chloride from neurons |
| Description | The development of a novel light-sensitive membrane protein that, when activated, drives chloride out of cells. The usefulness of this is that there is considerable evidence that a primary pathology in many types of epilepsy arises from a failure to regulate neuronal chloride levels, leading to the build up of chloride inside cells. Our novel strategy allowed a direct test of this hypothesis and may provide therapeutic avenues. |
| IP Reference | GB1601008.4 |
| Protection | Patent granted |
| Year Protection Granted | 2016 |
| Licensed | No |
| Impact | This work continues to be a major focus of Dr Trevelyan's laboratory. They will continue this work in parallel with the CANDO project, and aim to bring in further research funds to test the strategy for modulating neuronal activity, and in particular epileptic activity, in more sophisticated animal models, including in vivo. |